tetano
Editor, Senior Moderator
Vaccine
. 2023 Jan 27;S0264-410X(23)00088-9.
doi: 10.1016/j.vaccine.2023.01.056. Online ahead of print.
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina
María Gabriela Matta[SUP] 1 [/SUP], Laura Pulido[SUP] 2 [/SUP], Juan José Herrera-Paz[SUP] 3 [/SUP], José M Picco[SUP] 4 [/SUP], Sebastian Wolff[SUP] 4 [/SUP], Gary Tse[SUP] 5 [/SUP], Sebastian Garcia-Zamora[SUP] 6 [/SUP]
Affiliations
Abstract
Immunizations for influenza and pneumococcus are effective interventions in reducing morbidity and mortality. The objective of this study was to describe the vaccination rates in volunteers from three regions of Argentina during the COVID-19 pandemic. In 2020, 3853 adults were surveyed, 61.6 % were females, 45 % were aged between 40 and 60 and 18.6 % were > 60 years old. The commonest comorbidities were hypertension (12.9 %), dyslipidemia (8.5 %), and smokers or former smokers (9.2 %). The global influenza vaccination rate was 37.7 %, pneumococcal vaccination 24.7 %, and both 17.8 %. Multivariable regression showed that the vaccination rate increased with age and the presence of comorbidities. However, in the subgroup with indications for both vaccines, 71.7 % had the influenza vaccine, 59 % had the pneumococcal vaccine, and 28.3 % received neither. Our study suggests that influenza and pneumococcal vaccine percentages in high-risk patients in Argentina remain sub-optimal. Immunizations with proven reductions in morbimortality could have also been relegated during the COVID pandemic.
Keywords: Immunization; Influenza vaccine; Pneumococcal vaccine.
. 2023 Jan 27;S0264-410X(23)00088-9.
doi: 10.1016/j.vaccine.2023.01.056. Online ahead of print.
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina
María Gabriela Matta[SUP] 1 [/SUP], Laura Pulido[SUP] 2 [/SUP], Juan José Herrera-Paz[SUP] 3 [/SUP], José M Picco[SUP] 4 [/SUP], Sebastian Wolff[SUP] 4 [/SUP], Gary Tse[SUP] 5 [/SUP], Sebastian Garcia-Zamora[SUP] 6 [/SUP]
Affiliations
- PMID: 36725429
- PMCID: PMC9885296
- DOI: 10.1016/j.vaccine.2023.01.056
Abstract
Immunizations for influenza and pneumococcus are effective interventions in reducing morbidity and mortality. The objective of this study was to describe the vaccination rates in volunteers from three regions of Argentina during the COVID-19 pandemic. In 2020, 3853 adults were surveyed, 61.6 % were females, 45 % were aged between 40 and 60 and 18.6 % were > 60 years old. The commonest comorbidities were hypertension (12.9 %), dyslipidemia (8.5 %), and smokers or former smokers (9.2 %). The global influenza vaccination rate was 37.7 %, pneumococcal vaccination 24.7 %, and both 17.8 %. Multivariable regression showed that the vaccination rate increased with age and the presence of comorbidities. However, in the subgroup with indications for both vaccines, 71.7 % had the influenza vaccine, 59 % had the pneumococcal vaccine, and 28.3 % received neither. Our study suggests that influenza and pneumococcal vaccine percentages in high-risk patients in Argentina remain sub-optimal. Immunizations with proven reductions in morbimortality could have also been relegated during the COVID pandemic.
Keywords: Immunization; Influenza vaccine; Pneumococcal vaccine.